Here we report a novel compound BCR-ABL mutation causing multi-TKI resistance CML as well as structural BCR-ABL changes induced by this mutant associated with multiple kinase inhibitor resistance. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.